Vnitr Lek 2007, 53(12):1310-1318

Diabetes mellitus and microalbuminuria

D. Krusová
II. interní klinika LF MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.

Microalbuminuria is considered as an independent predictor of cardiovascular morbidity and mortality and is a general marker of endothelial dysfunction. Microalbuminuria is the indicator of the incipient phase of diabetic nephropathy in diabetes mellitus, and especially in the type 1 diabetes mellitus patients. Progressive continuously growing albumin secretion into the urine is a generally recognised criterion for determining the degree of diabetic renal affection. The modern definition of diabetic nephropathy therefore includes increased cardiovascular risk which - if not treated - is accompanied by progressive decrease in renal functions related to diabetic retinopathy. In the case of a positive microalbuminuria result, strict monitoring of diabetes compensation and of systemic pressure is necessary in order to prevent further progression of specific microvascular complications of diabetes. The article provides an overview of epidemiological data and current knowledge of etiopathogenesis of microalbuminuria in diabetic nephropathy.

Keywords: diabetes mellitus; diabetic nephropathy; microalbuminuria; ACE-inhibitors

Received: June 13, 2007; Accepted: August 3, 2007; Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krusová D. Diabetes mellitus and microalbuminuria. Vnitr Lek. 2007;53(12):1310-1318.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marshall SM. Clinical features and management of diabetic nephropathy. In: Textbook of Diabetes. 3rd ed. Oxford: Blackwell Science 2006; 53.1-53.22.
    2. Deckert T, Feldt-Rasmussen B, Borch-Johnsen A et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226. Go to original source... Go to PubMed...
    3. Mogensen CE, Eiskjaer C. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18: 572-581. Go to original source... Go to PubMed...
    4. Shaw KM. Diabetic complications. 1st ed. Chichester (UK): John Wiley Sons 1996; 27-52.
    5. Škrha J. Laboratorní ukazatel diabetické nefropatie. Sborník na téma diabetické nefropatie při příležitosti XXIX. diabetologických dní. Luhačovice 1993; 22-29.
    6. Perušičová J, Rosolová H, Kvapil M. Mikroalbuminurie. In: Trendy soudobé nefrologie. Praha: Galén 1999; 121-135.
    7. Bakker A. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313. Go to original source... Go to PubMed...
    8. Tesař V. Vliv léčby inhibitory angiotentin konvertujícího enzymu a antagonisty angiotenzinu II na vývoj diabetické nefropatie ve stádiu Mikroalbuminurie. In: Perušičová J, Kvapil M, Matoulek M. Trendy soudobé nefrologie. Diabetická nefropatie. Praha: Galén 2003; 11-54.
    9. Allen T, Cao Z, Youssef S et al. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46: 1612-1618. Go to original source... Go to PubMed...
    10. Bakris GL, Weir MR, De Quatro V et al. Effects of an ACE inhibitors/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289. Go to original source... Go to PubMed...
    11. Bartoš V, Bouček P. Diabetická nefropatie. Praktická diabetologie. Praha: Maxdorf 1996; 181-197.
    12. Bartoš V. Standardy péče při diabetické nefropatii. DMEV 1998; 2: 97-79.
    13. Chatuverdi N, Bandinelli S, Mangili R et al. Microalbuminuria in type 1 diabetes:rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-227. Go to original source... Go to PubMed...
    14. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46(Suppl 2): S104-S111. Go to original source... Go to PubMed...
    15. Mackin P, MacLeod JM, New J. Renal function in long-duration type 1 diabetes. Diabetes Care 1996; 39: 1116-1124. Go to original source... Go to PubMed...
    16. Caliskan S. Tubular markers in children with insulin-dependent diabetes mellitus. Turk J Pediatr 1997; 39: 213-218.
    17. Hong CY, Chia KS. Markers of Diabetic Nephropathy. J Diabetes Complications 1998; 12: 43-60. Go to original source... Go to PubMed...
    18. Souček M, Widimsky J, Lanska V. Control of Hypertension in Patients with Hypertension, Diabetes and Impaired Fasting Glucose by Czech Primary Care Physician. Kidney Blood Press Res 2006; 29: 366-372. Go to original source... Go to PubMed...
    19. Heilig CW, Concepcion LA, Riser BL et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96: 1802-1814. Go to original source... Go to PubMed...
    20. Heilig CW, Kreisberg JI, Freytag S et al. Antisense GLT-1 protects mesangial cells from glucose induction of GLT-1 and fibronectin expression. Am J Physiol Renal Physiol 2001; 280: F657-F666. Go to original source... Go to PubMed...
    21. Gilbert RE, Cox A, Wu 2nd et al. Expression of TGF-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Nephro 1998; 47: 141-122. Go to original source...
    22. Brown NJ, Vaughan J, Douglas E. Angiotensin-Converting-Enzyme Inhibitors. Brown Circulation 1998; 97: 1411-1420. Go to original source... Go to PubMed...
    23. Poulsen PL. High normo- or low microalbuminuria: basis for intervention in IDDM. Kidney Int Suppl 1997; 63: 15-18.
    24. Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year prospective study. Diabet Med 1999; 16: 918-925. Go to original source... Go to PubMed...
    25. Agardh CD. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow up study of 44 adult patients in routine care. Diabetes Res Clin Pract 1997; 35: 113-121. Go to original source... Go to PubMed...
    26. Škrha J. Etiopatogeneza mikroangiopatických komplikací. Přednáška na celostátním diabetologickém sympóziu v Hradci Králové 4. 6. 1999.
    27. Cohen A. Prevention of Diabetic nephropathy. J Clin Investig 1995; 5: 2338-2345. Go to original source... Go to PubMed...
    28. Epstein M. The Benefits of ACE Inhibitors and Calcium Antagonists in Slowing Progressive Renal Failure. Renal Failure 1996; 18: 813-832. Go to original source... Go to PubMed...
    29. Gruden G, Thomas S, Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-737. Go to original source... Go to PubMed...
    30. Diabetes control and complication Trial (DCCT) Research group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the DCCT. Kidney Int 1995; 47: 1703-1720. Go to PubMed...
    31. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications on patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    32. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 853-865. Go to original source...
    33. Cooper ME. Renoprotection with antihypertensive agents in normotensive diabetic subjects. Diabetes Reviews International 1998; 7: 12-15.
    34. Yusuf S. From the Hope to the Ontarget and the Transcend studies: chelenges in improving prognosis. Am J Cardiol 2002; 89: 18A-26A. Go to original source... Go to PubMed...
    35. Hall PM. Prevention of progression in diabetic nephropathy. Diabetes Spectrum, 2006; 19: 18-24. Go to original source...
    36. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection, pharmacological rationale and evidence. J Hypertens 1998 (Suppl 16): S3-S9.
    37. Krusová D. Možnosti diagnostiky a terapeutického ovlivnění časných fází diabetické nefropatie. Doktorská disertační práce, MU LF 2001; 1-109.
    38. Erley CM. Subpressor doses of angiotensin II do not increase albumin excretion in humans. Clin Nephrology 1996; 46: 312-318.
    39. EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoaluminuria. Lancet 1997; 349: 1787-1792. Go to original source...
    40. Ravid M, Brosh D, Levi I et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Annals of Internal Medicine 1998; 128: 982-988. Go to original source... Go to PubMed...
    41. Krusová D, Ševela K. Incipientní stadium diabetické nefropatie a vliv kombinované terapie ACE-inhibitory a blokátory angiotenzinu II. Vnitř Lék 2004; 50(Suppl 1): 127-128.
    42. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007; 13: 1335-1345. Go to original source... Go to PubMed...
    43. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    44. Mogensen CE, Neldam S, Tikkanen I at al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444. Go to original source... Go to PubMed...
    45. Strippoli GF, Craig MC, Schena FP et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006; 17(Suppl 2): S153-S155. Go to original source... Go to PubMed...
    46. Held C, Gerstein HC, Yusuf S ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Comment in: Circulation 2007; 115: 1334-1335. Go to original source... Go to PubMed...
    47. Crepaldi G. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-110. Go to original source... Go to PubMed...
    48. Krusová D. Antihypertenziva a jejich význam v iniciálním stádiu diabetické nefropatie. Vnitř Lék 1999; 44: 664-669.
    49. Hrnčiar J, Hrnčiarová M, Jakubíková K. Miesto Ca-inhibitorov v liečbe artériovej hypertenzie. Vnitř Lék 1997; 43: 74-80. Go to PubMed...
    50. Parving HH, Tarnow L, Rossing P. Renal protection in diabetes, an emerging role for calcium antagonists. Cardiology 1997; 88(Suppl 3): 56-62. Go to original source... Go to PubMed...
    51. Chan JC. Antihypertensive and antialbuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without noninsulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80. Go to original source... Go to PubMed...
    52. Pomerleau J. Effect of protein intake on glycaemic control and renal function in typ 2 diabetes mellitus. Diabetologia 1993; 36: 829-834. Go to original source... Go to PubMed...
    53. Marshall SM. Strategies for monitoring diabetic nephropathy. Current Med Lit 1996; 13: 67-72.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.